Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InflaRx (IFRX) Cash & Equivalents (2016 - 2026)

InflaRx's Cash & Equivalents history spans 10 years, with the latest figure at $18.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 2.96% to $18.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.8 million, a 2.96% decrease, with the full-year FY2025 number at $18.7 million, up 308.98% from a year prior.
  • Cash & Equivalents hit $18.8 million in Q1 2026 for InflaRx, up from $18.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IFRX hit a ceiling of $29.5 million in Q1 2022 and a floor of $4.6 million in Q4 2024.
  • Historically, Cash & Equivalents has averaged $18.0 million across 5 years, with a median of $17.7 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 66.8% in 2024 and later surged 308.98% in 2025.
  • Tracing IFRX's Cash & Equivalents over 5 years: stood at $16.6 million in 2022, then fell by 17.22% to $13.7 million in 2023, then tumbled by 66.8% to $4.6 million in 2024, then surged by 308.98% to $18.7 million in 2025, then grew by 0.58% to $18.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for IFRX at $18.8 million in Q1 2026, $18.7 million in Q4 2025, and $21.5 million in Q3 2025.